<DOC>
	<DOCNO>NCT02045953</DOCNO>
	<brief_summary>The VENTOLIN Mini-Spacer develop order support patient Emerging Markets Asia Pacific region access affordable spacers . The aim exploratory study investigate whether systemic exposure fluticasone propionate ( FP ) salmeterol observe VENTOLIN Mini-Spacer comparable systemic exposure FP salmeterol observe Trudell Aerochamber Plus spacer FLIXOTIDE SERETIDE Metered Dose Inhaler ( MDI ) product . There four study period study participant receive four study treatment study . The total duration study include screening , treatment period , washout period , follow-up period 58 day . Study plan enroll 20 healthy subject . VENTOLIN register trademark GlaxoSmithKline . FLIXOTIDE register trademark GlaxoSmithKline . SERETIDE register trademark GlaxoSmithKline .</brief_summary>
	<brief_title>A Study Assess Systemic Exposure FLIXOTIDE™ ( Fluticasone Propionate ) SERETIDE™ ( Fluticasone Propionate Salmeterol ) Given With VENTOLIN™ Mini-Spacer Compared Aerochamber Plus Spacer</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female subject 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac test . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index within range 19 34 kg/meter^2 ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document hysterectomy , bilateral oophorectomy bilateral salpingectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 21.7 international unit/Liter ( L ) estradiol &lt; 110 picomoles/L confirmatory ] . [ Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . ] Childbearing potential negative pregnancy test determine urine serum human Chorionic Gonadotropin ( hCG ) test screen prior dosing AND Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 2 day postlast dose . OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form . Agrees provide write consent information enter The Overvolunteering Prevention System `` TOPS '' . Alanine aminotransferase , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average QT duration correct heart rate Fridericia 's formula ( QTcF ) value single electrocardiogram ( ECGs ) obtain brief recording period : QTcF &lt; 450 millisecond ( msec ) . Exclusion Criteria Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( approximately 240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Positive smoking breath test history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test human immuno virus antibody . Pregnant female determine positive serum hCG test screen prior dosing . Loss 400 mL blood 3 month trial , e.g . blood donor . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug ( except simple analgesic ) , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid 7 day prior first subsequent dos study medication collection last PK sample study period . The subject unable use inhaler spacer device correctly train</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>Pharmocokinetics</keyword>
	<keyword>FLIXOTIDE</keyword>
	<keyword>VENTOLIN Mini-Spacer</keyword>
</DOC>